
Precision Medicine Equity Hinges on Systems, but Coverage Gaps Linger
Key Takeaways
- Precision medicine functions as an end-to-end system—patient identification, ordering, results return, and treatment action—and gaps at any step can worsen inequity.
- Dedicated infrastructure and EMR nudges can drive testing from ~50–60% to ~90–95% in advanced disease, while liquid biopsy helps overcome tissue-acquisition barriers.
Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.
Precision medicine can narrow gaps in cancer care only when testing, interpretation, and payment systems work for every patient. However, community practices say these systems are still being built. The discussion “Is Precision Medicine Making Cancer Care More or Less Equitable?” focused on this tension at the
This panel was moderated by Sucharu “Chris” Prakash, MD, director of quality services at Texas Oncology and medical director of precision medicine at
How Are Practices Closing Testing Gaps?
Oh said clinicians should think of precision medicine “not as a test or as a new advance for a specific drug, but really a system,” noting that advanced testing makes care less
Brisbin-Ferraro said Texas Oncology grew from approximately 1000 to 1500 genomic profiles per year when its dedicated program began to nearly 7000 orders per month, an increase she attributed to infrastructure that facilitated the process. Prakash said a biomarker testing initiative that launched in 2022 increased testing rates in advanced tumors from between 50% and 60% to between 90% and 95%,1 with Brisbin-Ferraro adding that the rate was 85% to 90% in metastatic disease. Prostate cancer continues to have the largest gap, she said.
Lung, prostate, and breast cancers lagged first, she said, because those tissues are hard to obtain. Liquid biopsy, with labs sending mobile phlebotomists to patients, helped close that gap.
Fugaro described a Flatiron Health pilot in
“You’re not forcing clinicians to remember what they need to test in which patient at the right time,” Fugaro said.
Kitchen cautioned that measuring performance is hard when results arrive from many vendors in many formats. “I think we all assume we’re doing better than we probably are,” he said.
Genomic Data and Trial Enrollment Still Skew
Genomic databases remain weighted toward people of European ancestry,2 the panelists noted. Oh said germline data gaps will not close without broad international efforts, and that testing patients where they live matters. For example, pathogenic variants in BRCA2 are the most prevalent among patients with breast cancer in Puerto Rico,3 yet patients on the island have been undertested for germline variants associated with prostate cancer.4
Fugaro said variants of unknown significance remain unclear because too little data exist, particularly for underrepresented subpopulations, and that sharing data starts with testing everyone appropriately.
Brisbin-Ferraro described a screening pilot for a KRAS G12C inhibitor trial in which Texas Oncology identified a larger share of African American and Hispanic patients than their share of the Texas and US populations. Those patients did not carry through to enrollment, however. The practice plans to explain why this was the case at a later time.
The panelists’ concerns echo recent research from more than 63,000 patients with advanced cancers, which found that patients with low socioeconomic status, Black or Hispanic patients, and those covered by Medicare or Medicaid are waiting significantly longer for next-generation sequencing in several tumor types.5,6
Can Coverage and Interpretation Keep Up?
Prakash said biomarker testing coverage legislation has passed in 25 states, including Texas, whose Senate Bill 989 was enacted in 2023,7 and that his practice has seen better payment patterns, fewer denials, and fewer requests for letters of medical necessity.8 Kitchen said he has not seen improved payer coverage in Utah.
Brisbin-Ferraro said Texas Medicaid now covers comprehensive genomic profiling, adding that clinicians who ordered testing through a clinical decision support tool in a pilot with the payer Superior HealthPlan avoided prior authorization for those patients, which meant fewer peer-to-peer reviews and faster results. Texas Oncology is pursuing a similar arrangement with Humana, she said. Oh said the pressure now falls on newer or off-label uses, such as MRD testing, where patients face denials or cost-sharing they cannot afford.
Interpretation is the next hurdle. Fugaro said results arrive as structured and unstructured, no standard genomic data set exists, and a biomarker such as PD-L1 means different things across tumor types. More information is not always better, she said, and although artificial intelligence (AI) may help, it will not always be the optimal solution.
“AI is as good as the data that it is trained on,” she said.
Oh described a patient case of a man in his 60s with newly metastatic prostate cancer who could receive chemotherapy, a PARP inhibitor, or an AKT inhibitor—each tied to a different biomarker. Kitchen said new FDA approvals are arriving at a fast pace, making up-to-date education a constant burden. Brisbin-Ferraro added that a pantumor approval does not mean a drug belongs in every tumor type. Prakash said it is “impossible for a community oncologist like me to keep up with every single advance that happens.”
References
- Brisbin L, Berry B, Schuchart T, et al. Innovative biomarker testing initiative in a community oncology setting. JCO Oncol Pract. 2023;19(11):385. doi:10.1200/OP.2023.19.11_suppl.385
- Fact sheet: participation in genomic research. National Human Genome Research Institute. Updated February 24, 2025. Accessed November 10, 2026.
https://www.genome.gov/about-genomics/fact-sheets/Participation-in-Genomic-Research - Diaz-Zabala HJ, Ortiz AP, Garland L, et al. A recurrent BRCA2 mutation explains the majority of hereditary breast and ovarian cancer syndrome cases in Puerto Rico. Cancers (Basel). 2018;10(11):419. doi:10.3390/cancers10110419
- Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR. Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):403-410. doi:10.1038/s41391-021-00469-3
- Hage Chehade C, Ozay ZI, Jo Y, et al. Trends and disparities in the use of next-generation sequencing in patients with cancer in the United States. JAMA Netw Open. 2026;9(4):e265585. doi:10.1001/jamanetworkopen.2026.5585
- McCrear S. SDOH drive disparities in NGS access across cancers. AJMC®. April 7, 2026. Accessed November 10, 2026.
https://www.ajmc.com/view/sdoh-drive-disparities-in-ngs-access-across-cancers - State biomarker testing coverage legislation advocacy campaign. Academy Health. Updated September 30, 2026. Accessed November 10, 2026.
https://academyhealth.org/initiatives/state-biomarker-testing-coverage-legislation-advocacy-campaign - Prakash S. Redefining standard of care: Texas Oncology’s model for universal biomarker testing. AJMC®. May 20, 2026. Accessed November 10, 2026.
https://www.ajmc.com/view/redefining-standard-of-care-texas-oncology-s-model-for-universal-biomarker-testing
Related to this article








